Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. cut its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 96.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,274 shares of the biotechnology company’s stock after selling 64,384 shares during the period. Balyasny Asset Management L.P.’s holdings in Axon Enterprise were worth $1,351,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in AXON. Wealth Enhancement Advisory Services LLC increased its position in Axon Enterprise by 1.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,607 shares of the biotechnology company’s stock worth $7,493,000 after buying an additional 185 shares during the period. Czech National Bank increased its holdings in shares of Axon Enterprise by 7.4% during the fourth quarter. Czech National Bank now owns 15,707 shares of the biotechnology company’s stock valued at $9,335,000 after purchasing an additional 1,082 shares during the period. Brookstone Capital Management increased its holdings in shares of Axon Enterprise by 27.0% during the fourth quarter. Brookstone Capital Management now owns 974 shares of the biotechnology company’s stock valued at $579,000 after purchasing an additional 207 shares during the period. MRA Advisory Group increased its holdings in shares of Axon Enterprise by 64.4% during the fourth quarter. MRA Advisory Group now owns 3,205 shares of the biotechnology company’s stock valued at $1,905,000 after purchasing an additional 1,255 shares during the period. Finally, 180 Wealth Advisors LLC acquired a new position in shares of Axon Enterprise during the fourth quarter valued at $220,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the sale, the chief executive officer now directly owns 3,063,982 shares in the company, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Joshua Isner sold 9,000 shares of the firm’s stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $683.31, for a total value of $6,149,790.00. Following the sale, the president now owns 308,714 shares of the company’s stock, valued at $210,947,363.34. The trade was a 2.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 19,964 shares of company stock worth $12,189,275 in the last quarter. 4.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Craig Hallum lowered Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. Needham & Company LLC raised their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Barclays raised their price target on Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a report on Friday, May 9th. JMP Securities reaffirmed an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Finally, The Goldman Sachs Group raised their target price on Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research note on Monday, January 27th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average target price of $640.91.

Axon Enterprise Trading Up 4.6%

NASDAQ:AXON opened at $724.77 on Wednesday. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a 1-year low of $273.52 and a 1-year high of $732.17. The firm has a market capitalization of $56.42 billion, a price-to-earnings ratio of 187.28, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24. The stock has a fifty day simple moving average of $572.18 and a 200 day simple moving average of $588.52.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The business had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. During the same quarter last year, the company posted $1.15 EPS. Axon Enterprise’s revenue for the quarter was up 31.3% on a year-over-year basis. Sell-side analysts forecast that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.